logo
Assembly Committee Votes to Expose Patients to Doctor Substance Abuse; Advances Bill to Overturn Law Requiring Medical Board Act When Doctors Fail Drug Test, Says Consumer Watchdog

Assembly Committee Votes to Expose Patients to Doctor Substance Abuse; Advances Bill to Overturn Law Requiring Medical Board Act When Doctors Fail Drug Test, Says Consumer Watchdog

SACRAMENTO, Calif., April 23, 2025 /PRNewswire/ — AB 408 by Assemblymember Berman to create a secret Medical Board program that will place patients at risk of harm at the hands of doctors abusing drugs or alcohol passed out of the Assembly Business & Professions Committee yesterday. The bill, AB 408 (Berman), would recreate a failed Medical Board 'diversion' program that allowed doctors under investigation by the Board because of substance abuse to evade discipline by entering the program. That program was shut down for putting patients at risk after failing five state audits and two reports by a Legislatively-appointed Enforcement Monitor. Consumer Watchdog testified in opposition to the bill in Sacramento on Tuesday. 'The bill would eliminate a basic patient safety responsibility of the Medical Board: that the Board investigate and act if it refers a doctor to treatment and that doctor fails a drug test,' testified Consumer Watchdog executive director Carmen Balber at the Tuesday hearing. The Legislature and the Board addressed the failures of the past diversion program by shutting that program down, and putting in place standards for monitoring doctors in diversion, a report to Medical Board enforcement staff, and consequences if a doctor referred to a diversion program fails a drug test or other program requirements. AB 408 does away with those protections. 'While keeping a failed drug test secret may be good for the doctor, it isn't good for patients being treated by that doctor,' said Balber. 'This isn't about doctors who voluntarily seek treatment; it would keep information secret about doctors who are already a clear and present danger to patients. If the board knows of a doctor's substance abuse, sends them to treatment, and then they fail a drug test, that fact can't be kept secret from the Board.' Read Consumer Watchdog's letter of opposition to AB 408.
Tina Minasian, an advocate for patient rights in California, suffers lifelong injuries inflicted by a substance-abusing surgeon who was a participant in the former confidential physician diversion program. Tina, along with other harmed patients, played a pivotal role in advocating for the closure of the prior failed Diversion Program. 'I can't believe that eighteen years later I have to take on this fight again on behalf of all Californians,' stated Minasian. 'We gained too many protections in the past fifteen years to give them up. I lost everything when I was harmed and cannot allow another Californian to endure what I did.' The History of the Medical Board and Physician Diversion The former confidential physician diversion program was subjected to a critical sunset review in 2007 after five failed audits by the state and a critical report from an Enforcement Monitor revealed significant failures in drug testing and oversight. In response, patients bravely stepped forward to share their harrowing stories of harm and loss due to the negligence of substance-abusing physicians. The Medical Board of California recognized the severity of these revelations and terminated the program in 2008. That same year, a pivotal hearing on the diversion program was convened at the state Capitol. Following, the chair of the joint committee announced the authorship of SB 1441, legislation designed to establish Uniform Standards for Substance-Abusing Health Care Professionals in California. Passed into law in 2008, SB 1441 was a vital step toward rectifying the failures of the previous diversion program. It empowered the Medical Board with essential tools to monitor substance-abusing licensees and enforce meaningful consequences for offending physicians, prioritizing the protection of patients and fostering a culture of accountability among healthcare providers. In 2016, SB 1177 was enacted, which allowed the Medical Board of California to recreate a new physician diversion program that adhered to the Uniform Standards. AB 408 discards those consumer protections and reconfigures any future program in the image of the failed diversion program.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Gambler bets some change on a slot machine in Florida — and wins big jackpot
Gambler bets some change on a slot machine in Florida — and wins big jackpot

Miami Herald

time13 minutes ago

  • Miami Herald

Gambler bets some change on a slot machine in Florida — and wins big jackpot

A gambler bet 88 cents on a slot machine at a Florida casino and won a big jackpot prize. The lucky player sat at a Fu Nan Fu Nu slot machine June 8 at Seminole Brighton Bay Hotel & Casino in Okeechobee, the casino said in a news release. The guest made a bet, hit spin and watched as the symbols flashed across the screen until a jackpot message appeared. The gambler then walked away $75,174.41 richer. Okeechobee is about a 70-mile drive northwest from West Palm Beach. Another gambler on the other side of the country also hit a slot machine jackpot with an 88-cent bet. The visitor sat at a Dancing Drums slot machine at Palms Casino Resort in Las Vegas and won a $28,733.01 jackpot, McClatchy News reported.

Judge Orders J&J Subsidiary to Pay $442 Million in Antitrust Lawsuit
Judge Orders J&J Subsidiary to Pay $442 Million in Antitrust Lawsuit

Yahoo

time13 minutes ago

  • Yahoo

Judge Orders J&J Subsidiary to Pay $442 Million in Antitrust Lawsuit

Johnson & Johnson (NYSE:JNJ) is one of the best Dow stocks to invest in. Recently, a federal judge ruled that a Johnson & Johnson subsidiary must pay $442 million in damages after a jury concluded last month that the company had broken antitrust laws by withholding support from hospitals that used reprocessed catheters. U.S. District Judge James Selna ordered the company to pay three times the $147 million in damages awarded by the jury, as permitted under antitrust regulations. This sum does not include legal fees or other related costs. Daniel Vukelich, CEO of the Association of Medical Device Reprocessors, described the decision as 'a seismic result.' In response, a Johnson & Johnson (NYSE:JNJ) spokesperson said the company intends to appeal the verdict but will comply with the court's decision and any required relief for now. The spokesperson added, 'We strongly disagree with the jury's verdict and believe it will not withstand appellate review.' Innovative Health sued Johnson & Johnson (NYSE:JNJ)'s Biosense Webster in 2019, claiming the company used its market power to block hospitals from using reprocessed heart-mapping catheters by tying support for its Carto 3 system to purchases of its own products. A jury found Johnson & Johnson (NYSE:JNJ) violated antitrust laws by withholding support for the reprocessed devices. AMDR's CEO said the ruling signals that anti-competitive tactics against reprocessing won't be tolerated. The case was heard in the U.S. District Court for the Central District of California. While we acknowledge the potential of JNJ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure. None.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store